Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca’s Brilinta Gives Brilliant Sales Performance

This article was originally published in The Pink Sheet Daily

Executive Summary

AstraZeneca’s cardiovascular drug Brilinta – one of the group’s five key growth platforms - seems to have turned the corner to give a stellar performance in the second quarter – particularly in the crucial US market.

You may also be interested in...



Emerging Markets Earnings Roundup: AstraZeneca (Part 12)

Who’s on first in China? That might be the a good question for AstraZeneca’s chief Pascal Soriot after the CEO of Pfizer also went out of his way to highlight second quarter success in the Middle Kingdom.

Research Fraud “Fruitful” Area For Government Probes; AstraZeneca Brilinta Trial In Crosshairs

HHS Office of Inspector General’s Mary Riordan advises drug makers to analyze their speaker programs and consulting arrangements for possible kickback activities.

Is Brilinta The Treatment To Keep AstraZeneca’s Lifeblood Flowing?

The company outlined plans to jumpstart growth of the anti-platelet drug Brilinta, including a 100% increase in marketing investment, increased rebates for payers and the addition of 200 nurse educators who will focus on the hospital discharge space.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS077514

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel